EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

By A. Midha, S. Dearden, R. McCormack. American Journal of Cancer Research, 2015

866 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020, background): “Several randomised, phase III trials have shown that EGFR tyrosine kinase inhibitors (TKIs) improve outcome in patients with EGFR-mutated NSCLC.27e30 Based on these data, these specific EGFR mutations reach the highest level in ESCAT.”
Lung adenocarcinoma promotion by air pollutants (2023, methodology): “(4) The RNA-seq was performed at two different sequencing centres and target depths were different.”